The Effect of Combination Lumacaftor and Ivacaftor on Markers of Hyperglycemia
NCT02858843 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1
Last updated 2018-05-21
Summary
The purpose of this research study is to find out if the combined therapy lumacaftor-ivacaftor affects glycemia in patient with cystic fibrosis.
Conditions
Interventions
- DRUG
-
lumacaftor-ivacaftor
Drug given for cystic fibrosis
Sponsors & Collaborators
-
Massachusetts General Hospital
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- SCREENING
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-08-01
- Primary Completion
- 2018-05-01
- Completion
- 2018-05-01
More Related Trials
-
Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease
NCT02390219 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
NCT02514473 ·Status: COMPLETED ·Phase: PHASE3
-
Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation
NCT03061331 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation
NCT01807949 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
NCT01897233 ·Status: COMPLETED ·Phase: PHASE3
-
Ivacaftor (Kalydeco) and Insulin in Cystic Fibrosis (CF)
NCT02039986 ·Status: COMPLETED
-
A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del
NCT03625466 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del
NCT02797132 ·Status: COMPLETED ·Phase: PHASE3
-
Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor
NCT03512119 ·Status: COMPLETED
-
A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
NCT03125395 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor
NCT01899105 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation
NCT01614470 ·Status: COMPLETED ·Phase: PHASE3
-
A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation
NCT02823470 ·Status: TERMINATED ·Phase: PHASE4
-
Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function
NCT01685801 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
NCT03601637 ·Status: COMPLETED ·Phase: PHASE3
-
ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor
NCT02807415 ·Status: COMPLETED
-
Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation
NCT01946412 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation
NCT04235140 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Lumacaftor/Ivacaftor in Children With Cystic Fibrosis Homozygote for F508del on Small Airway Function
NCT04138589 ·Status: COMPLETED
-
An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations
NCT02934698 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)
NCT01614457 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation
NCT02742519 ·Status: TERMINATED ·Phase: PHASE3
-
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation
NCT02725567 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children
NCT04509050 ·Status: RECRUITING
-
A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation
NCT03068312 ·Status: COMPLETED ·Phase: PHASE3